It is time to move forward into the era of Theranostics

被引：10
作者：
Ahmadzadehfar, Hojjat [1 ]
Essler, Markus [1 ]
机构：
[1] Univ Hosp Bonn, Dept Nucl Med, Sigmund Freud Str 25, D-53127 Bonn, Germany
来源：
EJNMMI RESEARCH | 2018年 / 8卷
关键词：
Theranostics; Radionuclide therapy; Oncology; Fellowship;
D O I：
10.1186/s13550-018-0364-x
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
Radionuclide therapy, which until 15 years ago included only a few approved therapies, is gaining importance in the treatment of various malignancies. The future of oncology will not be limited to surgery, chemo-, antibody therapies or external radiation; it will include targeted therapy with radionuclides, which will become the standard of care for a variety of malignant diseases in combination or as an alternative to other therapies. Therefore there is a need to train Nuclear Oncologists, who are able to approach oncological diseases, promote development of radiopharmacy, understand the biology of radionuclide treatment, apply radionuclide treatments and be able to use molecular imaging such as PET/CT and SPECT/CT for treatment planning and dosimetry.
引用
收藏
页数：2
相关论文
共 86 条
[1]  
Braat AJ(2015)(9)(0)Y hepatic radioembolization: an update on current practice and recent developments J Nucl Med 56 1079-1087
[2]  
Smits ML(2017)Safety of multiple repeated cycles of 177Lu-octreotate in patients with recurrent neuroendocrine tumour Eur J Nucl Med Mol Imaging 44 1207-1214
[3]  
Braat MN(2012)Yttrium-labelled peptides for therapy of NET Eur J Nucl Med Mol Imaging 39 S93-102
[4]  
van den Hoven AF(2007)EANM procedure guideline for radio-immunotherapy for B-cell lymphoma with 90Y-radiolabelled ibritumomab tiuxetan (Zevalin) Eur J Nucl Med Mol Imaging 34 616-622
[5]  
Prince JF(2011)Internal radiotherapy of painful bone metastases Methods 55 258-270
[6]  
de Jong HW(2015)Early side effects and first results of radioligand therapy with (177)Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study EJNMMI Res 5 114-1454
[7]  
Yordanova A(2017)Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [177Lu]Lu-PSMA-617 Eur J Nucl Med Mol Imaging 44 1448-55574
[8]  
Mayer K(2017)Radioligand therapy of metastatic prostate cancer using 177Lu-PSMA-617 after radiation exposure to 223Ra-dichloride Oncotarget 8 55567-90
[9]  
Brossart P(2017)The impact of repeated cycles of radioligand therapy using [177Lu]Lu-PSMA-617 on renal function in patients with hormone refractory metastatic prostate cancer Eur J Nucl Med Mol Imaging 44 1473-14
[10]  
Gonzalez-Carmona MA(2017)German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients J Nucl Med 58 85-649
123456789